FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025754345> ?p ?o ?g. }

• W2025754345 endingPage "996" @default.
• W2025754345 startingPage "994" @default.
• W2025754345 abstract "<h3>Introduction</h3> Vedolizumab. (VDZ) is an α4β7 integrin antagonist licensed to treat moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD). We provide long-term real-world data on outcomes after VDZ discontinuation. <h3>Methods</h3> A consecutive cohort of 193 adult IBD patients initiated on VDZ between May 2015 and June 2019 was retrospectively reviewed up to June 2020. Primary outcomes were post-VDZ relapse, biologic and surgical event rates. VDZ discontinuation for remission was classified as treatment for at least 6 months with 3 months corticosteroid-free clinical remission pre-discontinuation. Statistics: Continuous variables (median, interquartile ranges (IQR), Mann–Whitney U- test); categorical variables (frequency, percentages, chi-square test). <h3>Results</h3> Data from 90 CD and 103 UC patients was analysed. Prior biologic exposure (Adalimumab 57.5% (111/193); Infliximab 46.6% (90/193); Ustekinumab in CD 42.2% (38/90)) was high overall. Total all-cause VDZ discontinuation rate was 74.4% (67/90) in CD and 56.3% (58/103) in UC with the majority discontinuing within year 1 (CD: <i>n</i> = 44; UC: <i>n</i> = 35) as compared to years 2, 3 or greater (CD: <i>n</i> = 13, 8, 2; UC: <i>n</i> = 11, 6, 7). Of these patients, 77.6% (52/67) with CD and 63.8% (37/58) with UC required another biologic. A majority with CD persisted on subsequent Ustekinumab (68%; 30/44) or anti-TNF (71%; 5/7) by the end of the study period. In UC, 26% (7/27) persisted on an anti-TNF and 64% (7/11) on Tofacitinib (Table 1). 17 patients were retreated with VDZ having discontinued it for remission (CD: <i>n</i> = 7; UC:<i> n</i> = 10). The median duration of VDZ retreatment was 164 [IQR: 87-189] weeks for CD and 165 [IQR: 126-205] weeks for UC (duration follow-up from first VDZ discontinuation for CD: 46 [IQR: 30-56] weeks; UC: 46 [IQR: 16-77] weeks). Of this larger cohort, there was no significant difference in relapse rate on VDZ retreatment between CD and UC (14% (<i>n</i> = 1) vs. 30% (<i>n</i> = 3), <i>p</i> = 0.6029)). A large minority of patients underwent subsequent surgery (CD: 38.8% (26/67); UC: 29.3% (17/59) with the median interval to surgery greatest in UC (CD: 21 (IQR: 9-71) vs. UC 63 (IQR: 12-84) weeks, <i>p</i> = 0.2409). Most CD patients who had surgery post VDZ (61.5%, 16/26) had had 2 prior biologics as compared to none who had VDZ first line (<i>p</i> = 0.184) whereas in UC, biologic exposure had less impact on surgery rate (<i>p</i> = 0.592). <h3>Conclusions</h3> Our data suggests VDZ recapture for relapse following discontinuation of therapy for remission, sequencing Ustekinumab after VDZ in complex/refractory CD and anti-TNF therapy before or after VDZ in UC are options in the management algorithm of IBD." @default.
• W2025754345 created "2016-06-24" @default.
• W2025754345 creator A5062611452 @default.
• W2025754345 creator A5063022901 @default.
• W2025754345 date "2001-10-27" @default.
• W2025754345 modified "2023-09-25" @default.
• W2025754345 title "Management of diabetes: are doctors framing the benefits from the wrong perspective?" @default.
• W2025754345 cites W1968075762 @default.
• W2025754345 cites W1976787772 @default.
• W2025754345 cites W1979295763 @default.
• W2025754345 cites W2000804425 @default.
• W2025754345 cites W2006893169 @default.
• W2025754345 cites W2015818981 @default.
• W2025754345 cites W2032217963 @default.
• W2025754345 cites W2048179962 @default.
• W2025754345 cites W2083793380 @default.
• W2025754345 cites W2083972549 @default.
• W2025754345 cites W2302447233 @default.
• W2025754345 cites W2760585829 @default.
• W2025754345 cites W2769264260 @default.
• W2025754345 cites W4239315519 @default.
• W2025754345 doi "https://doi.org/10.1136/bmj.323.7319.994" @default.
• W2025754345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1121514" @default.
• W2025754345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11679393" @default.
• W2025754345 hasPublicationYear "2001" @default.
• W2025754345 type Work @default.
• W2025754345 sameAs 2025754345 @default.
• W2025754345 citedByCount "115" @default.
• W2025754345 countsByYear W20257543452012 @default.
• W2025754345 countsByYear W20257543452013 @default.
• W2025754345 countsByYear W20257543452014 @default.
• W2025754345 countsByYear W20257543452015 @default.
• W2025754345 countsByYear W20257543452016 @default.
• W2025754345 countsByYear W20257543452017 @default.
• W2025754345 countsByYear W20257543452018 @default.
• W2025754345 countsByYear W20257543452019 @default.
• W2025754345 countsByYear W20257543452020 @default.
• W2025754345 countsByYear W20257543452021 @default.
• W2025754345 countsByYear W20257543452022 @default.
• W2025754345 countsByYear W20257543452023 @default.
• W2025754345 crossrefType "journal-article" @default.
• W2025754345 hasAuthorship W2025754345A5062611452 @default.
• W2025754345 hasAuthorship W2025754345A5063022901 @default.
• W2025754345 hasBestOaLocation W20257543452 @default.
• W2025754345 hasConcept C12713177 @default.
• W2025754345 hasConcept C127413603 @default.
• W2025754345 hasConcept C154945302 @default.
• W2025754345 hasConcept C169087156 @default.
• W2025754345 hasConcept C2522767166 @default.
• W2025754345 hasConcept C41008148 @default.
• W2025754345 hasConcept C66938386 @default.
• W2025754345 hasConcept C71924100 @default.
• W2025754345 hasConceptScore W2025754345C12713177 @default.
• W2025754345 hasConceptScore W2025754345C127413603 @default.
• W2025754345 hasConceptScore W2025754345C154945302 @default.
• W2025754345 hasConceptScore W2025754345C169087156 @default.
• W2025754345 hasConceptScore W2025754345C2522767166 @default.
• W2025754345 hasConceptScore W2025754345C41008148 @default.
• W2025754345 hasConceptScore W2025754345C66938386 @default.
• W2025754345 hasConceptScore W2025754345C71924100 @default.
• W2025754345 hasIssue "7319" @default.
• W2025754345 hasLocation W20257543451 @default.
• W2025754345 hasLocation W20257543452 @default.
• W2025754345 hasLocation W20257543453 @default.
• W2025754345 hasLocation W20257543454 @default.
• W2025754345 hasOpenAccess W2025754345 @default.
• W2025754345 hasPrimaryLocation W20257543451 @default.
• W2025754345 hasRelatedWork W1506200166 @default.
• W2025754345 hasRelatedWork W1995515455 @default.
• W2025754345 hasRelatedWork W2048182022 @default.
• W2025754345 hasRelatedWork W2080531066 @default.
• W2025754345 hasRelatedWork W2604872355 @default.
• W2025754345 hasRelatedWork W2748952813 @default.
• W2025754345 hasRelatedWork W2899084033 @default.
• W2025754345 hasRelatedWork W3031052312 @default.
• W2025754345 hasRelatedWork W3032375762 @default.
• W2025754345 hasRelatedWork W3108674512 @default.
• W2025754345 hasVolume "323" @default.
• W2025754345 isParatext "false" @default.
• W2025754345 isRetracted "false" @default.
• W2025754345 magId "2025754345" @default.
• W2025754345 workType "article" @default.